NCT06993662

The Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective.

The Effectiveness and Efficacy of the Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective for Patients With Mental Health Disorders

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 107 (actual)
• Sponsor: Rakitzi, Stavroula · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The combination of pharmacotherapy and individual cognitive behavioral therapy in a private practice.

Detailed description

Reintegration into society and good functional outcome by people with mental health disorders is frequently the result of the combination of pharmacotherapy and individual cognitive behavioral psychotherapy. The effectiveness and efficacy of this combination of treatments under the recovery perspective by anxiety disorders, depressive disorders, PTSD, bipolar disorders, schizophrenia and psychotic disorders, by obsessive-compulsive disorders and by personality disorders presents the main goal of this research protocol. Recovery means that people learn through the trherapy to be responsible towards their own problems.

Conditions

• Anxiety
• Depression
• Obsessive-compulsive Disorder
• Personality Disorder
• Bipolar Disorder
• Schizophrenia
• Psychotic Disorders
• PTSD

Interventions

Type	Name	Description
COMBINATION_PRODUCT	Group A. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by anxiety disorders and depression.	The combination of pharmacotherapy (anxiolytics (tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI) and individual cognitive behavioral psychotherapy by anxiety disorders and depression.
COMBINATION_PRODUCT	Group B. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by PTSD	The combination of pharmacotherapy (anxiolytics (tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI) and individual cognitive behavioral psychotherapy by PTSD
COMBINATION_PRODUCT	Group C. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by obsessive-compulsive disorder.	The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by obsessive-compulsive disorder.
COMBINATION_PRODUCT	Group D.The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by bipolar disorder	The combination of pharmacotherapy (anxiolytics (tavor, clonotril, lexotanil) antidepressants (SSRI, SNRI), mood stabilizers (lithium, depakine), antipsychotics (clozapine and atypical antipsychotics)) and individual cognitive behavioral psychotherapy by bipolar disorder.
COMBINATION_PRODUCT	Group E. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by schizophrenia and psychotic disorders	The combination of pharmacotherapy (anxiolytics(tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI), antipsychotics (clozapine and atypical antipsychotics)) and individual cognitive behavioral psychotherapy by schizophrenia and psychotic disorders.
COMBINATION_PRODUCT	Group F.The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by personality disorders	The combination of pharmacotherapy (anxiolytics (tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI), antipsychotics (clozapine and atypical antipsychotics) and individual cognitive behavioral psychotherapy by personality disorders.

Timeline

• Start date: 2025-06-02
• Primary completion: 2027-12-20
• Completion: 2027-12-20
• First posted: 2025-05-29
• Last updated: 2026-02-06

Locations

1 site across 1 country: Greece

Regulatory

• FDA-regulated drug study